Literature DB >> 15158550

Noncosmetic uses of botulinum toxin.

Boris Bentsianov1, Craig Zalvan, Andrew Blitzer.   

Abstract

Since the introduction of botulinum toxin (BTX) as a therapeutic tool in the 1970s, the number of uses for this substance has increased exponentially. BTX's mechanism of action involves degrading the SNARE proteins blockading the release of acetylcholine into the neuromuscular junction. In many body systems, decrease of contractility, strength, and tension of certain muscle groups result in improved clinical outcomes. Applications now include cosmetic, gastroenterologic, otolaryngologic, genitourinary, neurologic, and dermatologic uses. In fact, BTX can be considered as a potential treatment in any situation involving inappropriate or exaggerated muscle contraction. Currently, the FDA has approved BTX-A (Botox) for treating glabellar lines, blepharospasm, strabismus, hemifacial spasm, cervical dystonia, and spasticity. With the addition of cosmetic applications to the FDA's approval list, the use of BTX has increased dramatically.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158550     DOI: 10.1016/j.clindermatol.2003.12.030

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  6 in total

1.  Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.

Authors:  Libin Xiao; Yougui Pan; Xiaolong Zhang; Yong Hu; Li Cai; Zhiyu Nie; Lizhen Pan; Bing Li; Yijing He; Lingjing Jin
Journal:  Neurol Sci       Date:  2016-07-18       Impact factor: 3.307

2.  Botulinum toxin to improve lower facial symmetry in facial nerve palsy.

Authors:  S A Sadiq; S Khwaja; S R Saeed
Journal:  Eye (Lond)       Date:  2012-09-14       Impact factor: 3.775

3.  Intragastric injection of botulinum toxin A for the treatment of obesity.

Authors:  Reinhard Mittermair; Christian Keller; John Geibel
Journal:  Obes Surg       Date:  2007-06       Impact factor: 4.129

4.  Botulinum toxin abolishes sweating via impaired sweat gland responsiveness to exogenous acetylcholine.

Authors:  M Shibasaki; S L Davis; J Cui; D A Low; D M Keller; C G Crandall
Journal:  Br J Dermatol       Date:  2009-04-22       Impact factor: 9.302

5.  The use of botulinum neurotoxin type A (Botox) for headaches: a case review.

Authors:  Mia Oliver; Joanna MacDonald; Moez Rajwani
Journal:  J Can Chiropr Assoc       Date:  2006-12

6.  Management of Facial Synkinesis with a Combination of BTX-A and Biofeedback: A Randomized Trial.

Authors:  Abbas Ali Pourmomeny; Sahar Asadi; Ahmad Cheatsaz
Journal:  Iran J Otorhinolaryngol       Date:  2015-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.